BRVE

Conviction 0HealthcareScan · Fri, Oct 2, 2026

Inverted hammer

Braveheart Bio, Inc. (BRVE) closed at $21.26 (-0.70%) on Oct 2, 2026. Its latest daily candle is a inverted hammer. RSI(14) 39, -29.1% from its 52-week high, -28.7% year to date. Sector: Healthcare · Biotechnology.

BRVE$21.26-0.70%

ResistanceSupportVol 14Insider buy

Vol MA14 732.49K

Aug 6Aug 18Aug 28Sep 10Sep 22Oct 2

Braveheart Bio, Inc.Biotechnology

Price21.26

Change-0.70%

Gap-1.73%

Rel volume0.48×

Avg volume611.44K

Avg $ vol15.31M

SMA 2024.87

SMA 50—

SMA 200—

Price vs 50—

Price vs 200—

MA stack—

50/200 cross—

Supertrenddown · 28.37

RSI (14)39

MACD hist-0.40

MACD cross—

Stoch %K / %D14 / 11

ADX (14)26

+DI / −DI8 / 21

RSI divergence—

MACD divergence—

ATR %10.96%

ADR %9.55%

52w high30.00

52w low20.20

From 52w high-29.13%

Above 52w low+5.25%

New 52w highNo

SqueezeOff

Bollinger width49.82%

%B0.21

Donchian pos13.68%

Donchian high29.97

Donchian low19.88

AVWAP (52w high)25.89

vs AVWAP high-17.88%

AVWAP (52w low)21.27

vs AVWAP low-0.06%

OBV trendFlat

Chaikin MF (20)-0.14

Today vs 20d0.48×

Avg vol (14d)732.49K

Avg vol (20d)611.44K

Avg $ vol (20d)15.31M

Market cap1.91B

RS Rating—

RS 3m (vs SPY)—

RS 6m (vs SPY)—

RS line new highNo

Trend template—

Technical rank18.1

1 week+3.10%

1 month-21.11%

3 months—

6 months—

1 year—

YTD-28.66%

P/E—

P/B-19.96

P/S—

P/FCF—

EPS—

Div yield—

ROE—

ROA—

Debt/Eq—

Current13.63

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth—

Price target45.25

Target upside112.84%

Analyst ratingBuy

Institutional—

Ent. value1.79B

Revenue—

Net income-14.99M

Gross profit—

Free cash flow—

IndustryBiotechnology

ExchangeNasdaq

Shares out—

Employees—

Listed—

Free float—

Float %—

Short interest1.4M

Days to cover5.6d

Short volume89.8%

Squeeze score75 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$2.51 vs −$0.25

Last surprise-904.0% miss

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank18.1 / 100

Group rank14 / 100

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmInverted hammer

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in BRVE

All disclosures →

No recent disclosed trades by Congress in BRVE. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in BRVE · open-market 5 buys

Insider	Side	Shares	Value	Traded	Filed
AH Bio Fund IV, L.P. 10% owner · Common Stock · 2026-08-07	Buy	1.1M	$20M	2026-08-07	2026-08-11
AH Bio Fund IV, L.P. 10% owner · Common Stock · 2026-08-07	Convert	9.13M	—	2026-08-07	2026-08-11
AH Bio Fund IV, L.P. 10% owner · Series A Preferred Stock · 2026-08-07	Convert	40M	—	2026-08-07	2026-08-11
ORBIMED ADVISORS LLC Director · Common Stock · 2026-08-07	Convert	9.13M	—	2026-08-07	2026-08-11
ORBIMED ADVISORS LLC Director · Common Stock · 2026-08-07	Buy	1.67M	$30M	2026-08-07	2026-08-11
ORBIMED ADVISORS LLC Director · Common Stock · 2026-08-07	Buy	273.33K	$4.9M	2026-08-07	2026-08-11
ORBIMED ADVISORS LLC Director · Series A Preferred Stock · 2026-08-07	Convert	40M	—	2026-08-07	2026-08-11
Chimovits Erez Director · Common Stock · 2026-08-07	Convert	9.13M	—	2026-08-07	2026-08-11
Chimovits Erez Director · Common Stock · 2026-08-07	Buy	1.67M	$30M	2026-08-07	2026-08-11
Chimovits Erez Director · Common Stock · 2026-08-07	Buy	273.33K	$4.9M	2026-08-07	2026-08-11

SEC filings

EDGAR filings in BRVE · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.

BRVE

Recent news

Get daily signals & real-time alerts.